Phase I/IIa Study of Pharmacokinetics and Safety of Atorvastatin in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease
Phase of Trial: Phase I/II
Latest Information Update: 25 Feb 2013
At a glance
- Drugs Atorvastatin (Primary)
- Indications Atherosclerosis; Coronary artery disease
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 25 Feb 2013 Additional lead trial centres added as reported by ClinicalTrials.gov record.
- 16 Nov 2012 Planned number of patients changed from 24 to 32 as reported by ClinicalTrials.gov.
- 16 Nov 2012 Planned End Date changed from 1 Jul 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.